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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
“Femilub®” and maintenance of vaginal moisture pursuant to Article 13(5) 
of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following  an  application  from  Nutrilinks  Sarl  submitted  for  authorisation  of  a  health  claim  pursuant  to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic 
Products, Nutrition and Allergies (NDA) was asked to provide a scientific opinion on a health claim related to 
“Femilub®” and maintenance of vaginal moisture. The food that is the subject of the health claim, “Femilub®”, 
which  is  a  combination  of  macadamia  oil,  borage  oil,  perilla  oil,  d-α-tocopherol  and  biotin,  is  sufficiently 
characterised.  The  claimed  effect,  maintenance  of  vaginal  moisture,  is  a  beneficial  physiological  effect.  No 
human  intervention  studies  were  provided  from  which  conclusions  could  be  drawn  for  the  scientific 
substantiation of the claim. A cause and effect relationship has not been established between the consumption of 
“Femilub®” and maintenance of vaginal moisture. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following an application from Nutrilinks Sarl submitted for authorisation of a health claim pursuant 
to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel 
on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to “Femilub®” and maintenance of vaginal moisture. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data.  
The food that is the subject of the health claim is  “Femilub®”, which is a food supplement that 
contains on average per capsule 450 mg macadamia oil, 146 mg borage oil and 10 mg perilla oil to 
which 2 mg d-α-tocopherol (total d-α-tocopherol content: 6 mg) and 8.2 µg biotin are added. The 
Panel considers that “Femilub®” is sufficiently characterised. 
The claimed effect proposed by the applicant is “reduction of vaginal dryness”. The target population 
proposed by the applicant is women with vaginal discomfort. Upon request from EFSA, the applicant 
confirmed that the claimed effect can be interpreted as maintenance of vaginal moisture. The Panel 
considers that maintenance of vaginal moisture is a beneficial physiological effect. 
One unpublished human intervention study (claimed as proprietary) was provided by the applicant as 
pertinent  to  the  claim.  This  was  a  randomised,  double-blind,  placebo-controlled  parallel  study  in 
40 women who indicated suffering from vaginal dryness and who were randomised to consume daily 
for four weeks either four tablets of “Femilub®” or placebo. Study groups differed with respect to 
menopausal  status  and  lubricant  use.  Intensity  of  vaginal  dryness  was  scored  by  subjects  in  a 
questionnaire on a 7-point scale, and intensity of itching and “intensity of inflammations” was scored 
by subjects on a 5-point scale. The Panel notes that even though the applicant was asked to provide a 
full  study  report,  only  a  summary  report  was  provided.  The  Panel  also  notes  that  the  evidence 
provided did not establish that the questionnaire used in the study was validated for the outcomes 
investigated, that the analysis of data did not take into account baseline values, differences between 
groups in post-menopausal status and lubricant use, that no information on the background diet of 
subjects was provided, that the study population was not sufficiently characterised in relation to the 
claimed effect, and that appropriate information on the method of randomisation and blinding was 
lacking. The Panel considers that no conclusions can be drawn from this study for the scientific 
substantiation of the claim. 
The Panel notes that no human intervention studies were provided from which conclusions could be 
drawn for the scientific substantiation of the claim.  
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of “Femilub®” and maintenance of vaginal moisture. 
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BACKGROUND 
Regulation (EC) No 1924/2006
3 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisation of health claims made on foods.  As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of  
this Regulation, are authorised in  accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 t hereof. In particular,  Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to  reduction in 
disease risk and to children’s development and health) which are based on newly developed scientific 
evidence, or which include a request for the protection of proprietary data, to the Community list of 
permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article  13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 04/05/2012. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed scientific evidence and included a request for the protection of proprietary data. 
  The scientific evaluation procedure started on 06/06/2012. 
  On 04/07/2012, the NDA Panel agreed on a list of questions for the applicant to provide 
additional  information  to  accompany  the  application,  and  the  clock  was  stopped  on 
06/07/2012 in compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
  The  clock  was  restarted  on  21/07/2012.  On  26/07/2012,  EFSA  received  the  requested 
information as submitted by the applicant.  
  During  its  meeting  on  12/09/2012,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to “Femilub®” 
and maintenance of vaginal moisture. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to “Femilub®” and maintenance of 
vaginal moisture. 
EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing of “Femilub®”, a positive assessment of its safety, nor a decision on whether “Femilub®” 
is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
                                                       
 
3  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. “Femilub®” and maintenance of vaginal moisture 
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It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. “Femilub®” and maintenance of vaginal moisture 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Nutrilinks Sarl, Chemin de Beau-rivage 7, Case postale 96 CH-1000 
Lausanne 21, Switzerland. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food which is the subject of the claim is “Femilub®”, which is a 
combination of macadamia oil, borage oil, perilla oil, d-α-tocopherol and biotin. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect relates to reducing vaginal dryness. 
Wording of the health claim as proposed by the applicant 
The following wordings are proposed by the applicant: “helps to reduce vaginal dryness”, “helps to 
reduce intimate dryness”, “helps to increase vaginal hydration” and “contributes to increase mucosa 
hydration”. 
Specific conditions of use as proposed by the applicant 
The applicant proposed the following conditions of use: Four capsules of “Femilub®” daily during 
four consecutive weeks during a meal. The target population proposed by the applicant is healthy 
adults in the general population and especially healthy women presenting vaginal discomfort. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food that is the subject of the health claim is “Femilub®”. 
“Femilub®” is a food supplement which contains per capsule on average 450 mg macadamia oil, 
146 mg borage oil and 10 mg perilla oil, to which 2 mg d-α-tocopherol (total d-α-tocopherol content: 
6 mg) and 8.2 µg biotin are added, with a fatty acid composition of around 47 % oleic acid (C18:1, 
n-9), 16 % palmitoleic acid (C16:1, n-7), 11 % linoleic acid (LA, C18:2, n-6), 9 % palmitic acid 
(C16:0),  5 %  γ-linolenic  acid  (GLA,  C18:3,  n-6),  3 %  stearic  acid  (C18:0),  3 %  eicosenoic  acid 
(C20:1, n-9), 2 % arachidic acid (C20:0) and 1 % α-linolenic acid (ALA, C18:3). Fatty acids, d-α-
tocopherol and biotin can be measured in foods by established methods. 
Information on the manufacturing process has been provided. According to the applicant, a stability 
study is in progress.  
Upon request from EFSA to provide information on how the individual constituents contained in 
“Femilub®” could contribute to the claimed effect, and to provide a rationale for the use of the 
specific combination of ingredients, the applicant indicated that for biotin and for vitamin E, health 
claims  on  the  maintenance  of  normal  mucous  membranes  and  the  protection  of  body  cells  from 
oxidative damage, respectively, have been authorised, and that GLA in borage oil and ALA in perilla 
oil would have an effect on skin hydration through a reduction in trans-epidermal water loss. The “Femilub®” and maintenance of vaginal moisture 
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applicant also stated that macadamia oil was chosen because of its content in oleic acid, without 
providing a rationale as to how oleic acid could contribute to the claimed effect. Upon a further 
request from EFSA to clarify how the amounts of fatty acids contained in “Femilub®” are related to 
usual intakes of these fatty acids through a balanced diet, the applicant indicated that habitual dietary 
intakes in France would provide 940 mg/day (men) and 740 mg/day (women) of ALA and 10.6 g/day 
(men) and 8.1 g/day (women) of LA (Astorg, 2004) and that the consumption of “Femilub®” would 
amount to an increase in intakes of ALA and LA of 2-3 %.  
The  Panel  considers  that  the  food,  “Femilub®”,  which  is  the  subject  of  the  health  claim,  is 
sufficiently characterised. 
2.  Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “reduction of vaginal dryness”. The target population 
proposed by the applicant is women with vaginal discomfort.  
Upon  request  from  EFSA,  the  applicant  confirmed  that  the  claimed  effect  can  be  interpreted  as 
maintenance of vaginal moisture. 
The level of vaginal moisture can be influenced by changes in blood oestrogen concentrations. A 
reduction in blood oestrogen concentrations may lead to a decrease in collagen and adipose content in 
the vulvar tissue, resulting in a decrease in the water-retaining ability of the vagina (Leclair and 
Anandarajah,  2002).  The  level  of  vaginal  moisture  can,  for  example,  be  assessed  by  using 
investigator-assessed vaginal fluid volume and vaginal moisture scores, or by using validated self-
administered questionnaires or visual analogue scales. 
The Panel considers that maintenance of vaginal moisture is a beneficial physiological effect. 
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in Pubmed, ScienceDirect, Blackwell Synergy, Wiley 
InterScience, Mary Ann Liebert, Scirus, IBIDS, SciFinder Scholar, Pascal, Google and SCOPUS from 
January 1970 to December 2011 with the following keywords: [“Femilub®”] and [“vaginal dryness” 
OR “atrophic vaginitis”]. The Panel notes the limitations of the literature search performed. 
The applicant did not identify any relevant studies from this search.  The applicant  provided one 
unpublished  human  intervention  study  (claimed  as  proprietary)  (Le  Breton  and  Lavigne,  2011, 
unpublished) as pertinent to the claim.  
In  a  randomised,  double-blind,  placebo-controlled  parallel  study  (Le  Breton  and  Lavigne,  2011, 
unpublished), 40 women who indicated suffering from vaginal dryness were randomised to consume 
daily  for  four  weeks  either  four  tablets  of  “Femilub®”  (n=20,  age  51.1±11.3  years,  75 %  post-
menopausal, 25 % using lubricants) or placebo (sunflower oil; n=20, mean age: 47.1±11.9 years, 
50 % post-menopausal, 50 % using lubricants). The use of hormone replacement therapy and other 
medication which could have an impact on vaginal moisture was not permitted throughout the study. 
The use of lubricants had not to be changed throughout the study. Intensity of vaginal dryness was 
scored by subjects in a questionnaire on a 7-point scale and intensity of itching and “intensity of 
inflammations” was scored by subjects on a 5-point scale. None of the subjects dropped out during 
the study. Differences from baseline between groups were analysed by the Mann-Whitney-U test. 
Upon request from EFSA on whether the study had been approved by an Ethics Committee, the 
applicant indicated that the study was a user test, and that no approval by an Ethics Committee was 
required according to French legislation. Upon another request from EFSA to clarify whether the 
questionnaire  used  in  the  study  was  validated  for  the  assessed  outcome  measures,  the  applicant 
provided information on a questionnaire other than the one used in the study and validated for the “Femilub®” and maintenance of vaginal moisture 
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assessment of female sexual function rather than vaginal dryness. The Panel notes that even though 
the applicant was asked to provide a full study report, only a summary report was provided. The Panel 
also notes that the evidence provided did not establish that the questionnaire used in the study was 
validated for the outcomes investigated, that the analysis of data did not take into account baseline 
values, differences between groups in post-menopausal status and lubricant use, that no information 
on  the  background  diet  of  subjects  was  provided,  that  the  study  population  was  not  sufficiently 
characterised in relation to the claimed effect, and that appropriate information on the method of 
randomisation and blinding was lacking. The Panel considers that no conclusions can be drawn from 
this study for the scientific substantiation of the claim. 
The Panel notes that no human intervention studies were provided from which conclusions could be 
drawn for the scientific substantiation of the claim.   
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of “Femilub®” and maintenance of vaginal moisture. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The food, “Femilub®”, which is the subject of the claim, is sufficiently characterised.  
  The claimed effect proposed by the applicant is “reduction of vaginal dryness”. The target 
population  proposed  by  the  applicant  is  women  with  vaginal  discomfort.  Maintenance  of 
vaginal moisture is a beneficial physiological effect. 
  A  cause  and  effect  relationship  has  not  been  established  between  the  consumption  of 
“Femilub®” and maintenance of vaginal moisture. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on “Femilub®” and maintenance of vaginal moisture pursuant to Article 
13(5)  of  Regulation  (EC)  No  1924/2006  (Claim  serial  No:  0346_BE).  May  2012.  Submitted  by 
Nutrilinks. 
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GLOSSARY AND ABBREVIATIONS 
ALA  α-Linolenic acid 
GLA  γ-Linolenic acid 
LA  Linoleic acid 